| Trial ID: | L6113 |
| Source ID: | NCT01189422
|
| Associated Drug: |
Teplizumab Or Placebo
|
| Title: |
Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes
|
| Acronym: |
SUBCUE
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 1 Diabetes Mellitus
|
| Interventions: |
DRUG: teplizumab or placebo
|
| Outcome Measures: |
Primary: Dose regimen, Define and evaluate dose regimen based on AEs, PD response and drug levels., 91 days |
|
| Sponsor/Collaborators: |
Sponsor: MacroGenics | Collaborators: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
1
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER
|
| Start Date: |
2010-08
|
| Completion Date: |
2011-02
|
| Results First Posted: |
|
| Last Update Posted: |
2022-02-08
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01189422
|
